Allergen Immunotherapy for the Prevention and Treatment of Asthma.

Autor: Batard T; Innovation & Science Department, Stallergenes Greer, Antony, France., Taillé C; Service de Pneumologie et Centre de référence pour les maladies respiratoires rares, Hôpital Bichat, AP-HP Nord-Université Paris Cité, Paris, France.; CRISALIS F-CRIN Network, Paris, France., Guilleminault L; Toulouse Institute for Infectious and Inflammatory Diseases (Infinity), INSERM UMR1291, CNRS UMR5051, University Toulouse III, Toulouse, France.; Department of Respiratory Medicine, Toulouse University Hospital, Faculty of Medicine, Toulouse, France.; CRISALIS/FCRIN, Toulouse, France., Bozek A; Clinical Department of Internal Diseases, Dermatology and Allergology, Medical University of Silesia, Katowice, Poland., Floch VB; Innovation & Science Department, Stallergenes Greer, Antony, France., Pfaar O; Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Philipps-Universität Marburg, Marburg, Germany., Canonica WG; Personalized Medicine, Asthma and Allergy, Humanitas Clinical and Research Center IRCCS, Milan, Italy.; Department of Biomedical Sciences, Humanitas University, Milan, Italy., Akdis C; Swiss Institute of Allergy and Asthma Research, University of Zurich, Davos, Switzerland., Shamji MH; National Heart and Lung Institute, Imperial College London, London, UK.; NIHR Imperial Biomedical Research Centre, London, UK., Mascarell L; Innovation & Science Department, Stallergenes Greer, Antony, France.
Jazyk: angličtina
Zdroj: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology [Clin Exp Allergy] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.
DOI: 10.1111/cea.14575
Abstrakt: Allergic asthma is the predominant phenotype among asthmatics. Although conventional pharmacotherapy is a central component in the management of asthma, it does not enable control of asthma symptoms in all patients. In recent decades, some uncontrolled asthmatic patients, especially those with allergic asthma, have benefited from biological therapies. However, biologics do not address all the unmet needs left by conventional pharmacotherapy. Furthermore, it is noteworthy that neither conventional pharmacotherapy nor biological therapies have disease-modifying properties. In this context, allergen immunotherapy (AIT) represents an indispensable component of the therapeutic arsenal against allergic asthma, due to its disease-modifying immunological effects. In this review article, funded by an AIT manufacturer, we find clinical trials support AIT as the only treatment option able both to improve allergic asthma symptoms and to prevent the onset and worsening of the condition. For patients with severe asthma or other safety concerns, the combination of AIT and biologics offers very promising new treatment modalities for the management of allergic asthma. Trial Registration: clinicaltrials.gov identifier: NCT06027073.
(© 2024 Stallergenes SAS and The Author(s). Clinical & Experimental Allergy published by John Wiley & Sons Ltd.)
Databáze: MEDLINE
Externí odkaz: